The Role of Dendritic Cells in Hepatitis C Infection

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00723242

Enrollment

Unknown

Registered

2008-07-28

Start date

2002-04-30

Completion date

2004-12-31

Last updated

2008-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis C Infection

Brief summary

The role of the dendritic cells, the most potent antigen presenting cells, in the establishment of chronic hepatitis C is not established. The study aims to define whether the dendritic cells are affected by the hepatitis C virus and whether that bears an impact on the antiviral immune response they generate. The hypothesis is explored by investigating a group of patients prior to and after the initiation of standard treatment for hepatitis C with pegylated Interferon and Ribavirin.

Interventions

DRUGViraferon-peg and Rebetol

Study design

Primary purpose

BASIC_SCIENCE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* anti-HCV positive * HCV RNA positive

Exclusion criteria

* contraindications for antiviral treatment * concurrent chronic viral infections

Design outcomes

Primary

Measure	Time frame
Basic science research (immunology of hepatitis C)in hepatitis c patients receiving established, standard antiviral treatment (pegylated Interferon+Ribavirin)	—

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026